

麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*

(a joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的有限公司)
(Stock Code 股份代號: 1513)

31 January 2024

Dear Non-registered Shareholders,

**Livzon Pharmaceutical Group Inc (the "Company") – Notice of Publication
Notice of publication of (1) Circular dated 31 January 2024; (2) Notice of the 2024 Second Extraordinary General Meeting;
and (3) Proxy Form (the "Current Corporate Communication") on website**

Please note that both the English and Chinese versions of the Current Corporate Communication are available electronically on the Company's website at www.livzon.com.cn and the HKEXnews website at www.hkexnews.hk. You may access the Current Corporate Communication by clicking the relevant title as appeared on the website of the Company or browsing through the HKEXnews website.

Collection of your electronic contact details

As a non-registered shareholder, to ensure timely receipt of the latest Corporate Communications or Notice of Publication by email, if you have not provided your email address to the Company or need to update your email address, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries. If the Company does not receive your functional email address from the Intermediaries, until such time that the functional email address is provided to the Intermediaries, you will be unable to receive any notifications via email regarding the publication of Corporate Communications and Notice of Publication.

Should you have any query on the above matters, please call the Hong Kong Share Registrar's enquiry hotline on (852) 2980 1333 from 9:00 am to 6:00 pm (Monday to Friday, excluding Hong Kong public holidays) or send an email to 1513-ecom@hk.tricorglobal.com.

Yours faithfully,
Livzon Pharmaceutical Group Inc.*

各位非登記股東:

麗珠醫藥集團股份有限公司(「本公司」) - 登載通知

(1)日期為二零二四年一月三十一日之通函; (2)二零二四年第二次臨時股東大會通知; 及(3)委任代表表格(「本次公司通訊文件」)已在網站登載通知

請注意, 本次公司通訊文件的英文版和中文版已上載於本公司網站 (www.livzon.com.cn) 和披露易網站 (www.hkexnews.hk), 可供查閱。閣下可在本公司網站按下相關標題網頁以閱覽本次公司通訊文件或在披露易網站瀏覽有關文件。

徵集 閣下之電子聯絡資料

作為非登記股東, 為確保及時收到最新的或透過電子郵件方式收取或接收公司通訊及登載通知, 如閣下尚未提供閣下之電子郵件地址予本公司, 或需更新閣下之電子郵件地址, 閣下應聯絡代閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公司(統稱「中介公司」), 並向閣下的中介公司提供閣下的電子郵件地址。如果本公司沒有從中介公司收到閣下的有效電子郵件地址, 閣下將無法透過電子郵件方式收取可供採取行動的公司通訊及登載通知。

如閣下對本函內容有任何疑問, 請致電本公司的香港股份過戶登記處電話熱線(852) 2980 1333, 辦公時間為星期一至五(公眾假期除外)上午9時正至下午6時正, 或電郵至 1513-ecom@hk.tricorglobal.com。

麗珠醫藥集團股份有限公司
謹啓

2024年1月31日